trolamine salicylate has been researched along with Infusion Site Adverse Event in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, N; Alanee, S; Crabtree, J; Deebajah, M; Delfino, K; El-Zawahry, A; McVary, K; Peabody, J; Pearce, T; Rao, K; Robinson, K; Sana, S | 1 |
1 trial(s) available for trolamine salicylate and Infusion Site Adverse Event
| Article | Year |
|---|---|
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Administration, Intravesical; Adrenal Insufficiency; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Arthralgia; Arthritis; BCG Vaccine; Carcinoma, Transitional Cell; Cardiomyopathies; Chest Pain; Cystoscopy; Edema; Female; Humans; Hypokalemia; Immune Checkpoint Inhibitors; Injection Site Reaction; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pulmonary Embolism; Urinary Bladder Neoplasms; Urinary Tract Infections; Wrist Joint | 2021 |